London, 18 May 2020, Consilium Strategic Communications, a global leader in strategic healthcare communications and investor relations, is pleased to announce the appointment of Ashley Tapp to the role of Senior Associate Partner, based in its London offices. In his new role, Ashley will be responsible for leading communications programmes for several of Consilium’s international clients.
Ashley is a healthcare and life sciences communications specialist with over 20 years of experience in a broad variety of in-house and agency roles, advising listed and private biotech, med-tech and pharmaceutical companies in the UK, Europe and North America.
“I’ve admired the work of Mary-Jane and the team at Consilium for several years so am very excited to be joining them. I look forward to sharing my expertise with clients to help them achieve their business objectives. The current COVID-19 pandemic has highlighted the importance of timely and accurate communications and working in this industry has never felt more important.”
Ashley Tapp
“The team and I are looking forward to working with Ashley and introducing him to clients. His broad international experience will be very useful, especially during these times of uncertainty and change when first rate engagement with corporate and investor audiences is essential.”
Mary-Jane Elliott
Managing Partner of Consilium Strategic Communications
Ashley joins Consilium from Instinctif Partners where he was an Associate Partner for nearly three years. Prior to joining Instinctif, Ashley was the Internal Communications Manager at Bristol Myers Squibb (NYSE: BMY) UK & Ireland for two years, during which time Opdivo® (nivolumab), the immuno-oncology medicine, was launched and the Company went through a significant modernisation. Before Bristol Myers Squibb, Ashley spent over six years working as a Communications Manager for BTG plc, a highly successful international specialist healthcare company which was bought out by Boston Scientific Corporation (NYSE: BSX) last year. During his time at BTG, the Company successfully completed a number of mergers and acquisitions, developing a well-respected interventional medicine business.
Ashley has a BSc (Hons) in Biology from Imperial College, London, including a year at the Université de Paris-Sud (XI) – Institut de Genetique et Microbiologie.
In his spare time Ashley is keen naturalist, cyclist and swimmer.
